Key Takeaways for AbbVie Stock as of July 2026
- Valuation Gap: TIKR’s model values AbbVie stock at $343 by December 2030, a 32% total return and 7% annualized versus the $259 close.
- Analyst Split: AbbVie stock has 16 buys, 6 holds, zero sells among 31 analysts.
- Dilution Trade: AbbVie’s $10.9B all-cash purchase of Apogee Therapeutics cuts adjusted EPS by $0.14 in 2026 and $0.46 in 2027 before turning accretive in 2032.
- Drawdown Reversal: AbbVie stock’s 19% drawdown bottomed April 27, 2026, and has narrowed to 0.65% below its high after first quarter revenue climbed 12% to $15B and adjusted EPS guidance rose to $14.08 to $14.28.
AbbVie Stock Trades Near-Term Pain for a $10.9 Billion Apogee Bet
AbbVie (ABBV) agreed on June 22, 2026 to acquire Apogee Therapeutics for $135.11 a share, a $10.9 billion all-cash deal that hands the company zumilokibart, a long-acting IL-13 antibody built for atopic dermatitis. The purchase implies roughly $10.1 billion net of Apogee’s cash, funded entirely with debt, and it lands while Skyrizi and Rinvoq are still beating the guidance AbbVie set for them just months earlier.
Skyrizi and Rinvoq combined for $6.602 billion in the first quarter alone, more quarterly revenue than Humira ever produced at its peak, which is exactly the base AbbVie is layering Apogee onto rather than replacing.
That bet carries an upfront cost. CFO Scott Reents laid out the math on the deal call: “We anticipate earnings accretion beginning in 2032 and significantly ramping over the long term… we anticipate the transaction to be approximately $0.14 dilutive to our adjusted earnings per share in 2026 and approximately $0.46 dilutive to earnings in 2027.” Six years of dilution is a long stretch to underwrite for a company that just posted 12.4% revenue growth and lifted full year adjusted EPS guidance to $14.08 to $14.28.
The payoff depends on how big zumilokibart actually gets. CEO Rob Michael set the bar for the deal without hedging: “our definition of mega blockbuster would be north of $10 billion.” Atopic dermatitis is growing more than 15% a year with penetration under 10%, and zumilokibart’s Phase II data held response rates out to a year on dosing every three to six months, a real edge over biologics injected monthly or every other week. Phase III trials begin in the second half of 2026, with a targeted launch in early 2030, and AbbVie is already lining up follow-on indications in asthma and chronic obstructive pulmonary disease through the same IL-13 platform.
AbbVie stock looks like it is not being repriced for what Skyrizi and Rinvoq already deliver. It is being repriced for whether a six-year wait on a $10.9 billion bet pays off in zumilokibart’s peak sales, and that gap between near-term earnings drag and the next decade’s growth is what actually moves ABBV stock from here.
AbbVie Stock Erases Its 19% Drawdown as Apogee Bet Weighs on Shares
AbbVie stock hit a maximum drawdown of 19% on April 27, 2026, two days before the first quarter earnings beat reset the narrative. Shares have clawed back nearly the entire decline and now sit just 0.65% below their high, even after absorbing the Apogee purchase and its multiyear dilution.
That recovery suggests the market is weighting Skyrizi and Rinvoq’s guidance raise more heavily than the near-term earnings hit from the Apogee deal.
Wall Street’s rating count on AbbVie stock stands at 16 buy, 8 outperform, 6 hold and 1 underperform, with zero analysts at sell. The mean target price sits at $268 against the $259 close, a gap of roughly 3% from today’s price. That target has climbed from $209 back in June 2025, tracking the same Skyrizi and Rinvoq outperformance that has powered the drawdown recovery.
TIKR Values AbbVie Stock at $343, Pricing In Zumilokibart’s Long Runway
TIKR’s mid case model values AbbVie stock at $343 by December 2030, implying a 32% total return from the current price of $259, or 7% annualized over 4.4 years.
That annualized rate places AbbVie stock’s forecast return above what investors typically expect from a mega-cap pharma trading mostly on dividend income, without needing a single near-term catalyst to hit the mark.
The target is reachable because AbbVie is stacking Apogee’s zumilokibart on top of Skyrizi and Rinvoq’s already-guided growth, not replacing it, and a mega blockbuster outcome for zumilokibart alone, on Rob Michael’s own bar of north of $10 billion, closes much of the gap between today’s $259 and the 2030 target.
Should You Invest in AbbVie Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up AbbVie Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track AbbVie Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ABBV stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
